What type of study is this?

September 10, 2025Open Access

Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes

Key Points

Residual cancer burden index serves as a significant prognostic marker in breast cancer, indicating survival outcomes post-chemotherapy.
Key evidence shows positive correlations between RCB scores and prognosis across different breast cancer subtypes during treatment.
Observational analysis evaluated RCB's prognostic performance in various molecular breast cancer subtypes receiving neoadjuvant chemotherapy.
Findings suggest that RCB could enhance prognostic strategies for individualized treatment plans in breast cancer management.

Abstract

The use of neoadjuvant chemotherapy (NAC) has improved outcomes in breast cancer (BC). The residual cancer burden index (RCB) predicts prognosis. This study evaluated RCB as a prognosticator in BC subtypes treated with NAC.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Valente et al. (Fri,) studied this question.

synapsesocial.com/papers/68c192459b7b07f3a0616551 https://doi.org/https://doi.org/10.4274/ejbh.galenos.2025.2025-5-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper